Plasma and Cerebrospinal Fluid Herpes Simplex Virus Levels at Diagnosis and Outcome of Neonatal Infection

doi:10.1016/j.jpeds.2014.11.011

The Journal of Pediatrics

Volume 166, Issue 4, April 2015, Pages 827-833

https://doi.org/10.1016/j.jpeds.2014.11.011 Get rights and content

Objective

To evaluate the utility of quantitative herpes simplex virus (HSV) polymerase chain reaction (PCR) levels for prognosis and management of neonatal HSV disease.

Study design

Clinical and virologic data were abstracted by medical record review from neonatal HSV cases treated at Seattle Children's Hospital between 1993 and 2012. HSV PCR results from plasma (n = 47), cerebrospinal fluid (n = 56), or both (n = 40) at the time of diagnosis were available from 63 infants; 26 with skin-eye-mouth (SEM), 18 with central nervous system (CNS), and 19 with disseminated (DIS) disease.

Results

Plasma HSV PCR was positive in 78% of the infants with SEM, 64% with CNS and 100% with DIS disease. Mean plasma viral level was 2.8 log₁₀ copies/mL in SEM, 2.2 log₁₀ copies/mL in CNS, and 7.2 log₁₀ copies/mL in DIS infants. The HSV levels were higher among infants who died compared with surviving infants, 8.1 log₁₀ copies/mL (range 7.7-8.6) vs 3.8 log10 copies/mL (range 0.0-8.6), P = .001, however, level of HSV DNA in the cerebrospinal fluid or in plasma did not correlate with neurologic outcome. Dynamics of HSV clearance from plasma during high-dose acyclovir treatment showed single-phase exponential decay with a median viral half-life of 1.26 days (range: 0.8-1.51).

Conclusions

Plasma HSV levels correlate with clinical presentation of neonatal HSV disease and mortality, but not neurologic outcome.

Section snippets

Methods

Medical records of all infants treated at SCH for virologically confirmed HSV infection during the neonatal period between the years 1993 and 2012 were reviewed. All infants with at least 1 HSV DNA PCR result from either CSF, plasma, or both were included. Standardized case report forms were used to extract maternal history of HSV infection (including HSV serology, if available), birth history, clinical presentation and laboratory tests, including coagulation studies, alanine aminotransferase

Results

Infants with neonatal HSV infection (n = 63) had HSV PCR results from plasma (n = 47), CSF (n = 56), or both (n = 40) at the time of diagnosis; 26 infants (41%) had SEM disease, 18 (29%) had CNS, and 19 (30%) had DIS disease (Table I). Infants presenting with CNS disease were older (mean age at diagnosis 17 days) than infants with SEM (mean age 9 days, P < .001) and DIS (mean age 7 days, P < .001) disease. More infants with CNS (15 of 18) vs SEM (7 of 26) disease were infected with HSV-2 (P

Discussion

In our large cohort of with virologically confirmed neonatal herpes, we found a clear association between the plasma HSV level, clinical presentation, and outcome, with death confined to children with very high plasma HSV levels at presentation. In contrast, clinical evidence of CNS disease, rather than CNS HSV level, predicted neurologic outcome. Decay of HSV in plasma in treated infants showed a single-phase exponential decay.

In the infants with DIS with serial viral levels, ACV had a uniform

References (39)

J.B. Cantey et al.
Use of blood polymerase chain reaction testing for diagnosis of herpes simplex virus infection
J Pediatr
(2012)
L. Corey et al.
Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome
Lancet
(1988)
A.C. Caviness et al.
Cost-effectiveness analysis of herpes simplex virus testing and treatment strategies in febrile neonates
Arch Pediatr Adolesc Med
(2008)
E. Anzivino et al.
Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention
Virol J
(2009)
D.W. Kimberlin
Diagnosis of herpes simplex virus in the era of polymerase chain reaction
Pediatr Infect Dis J
(2006)
D.W. Kimberlin et al.
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group
J Infect Dis
(1996)
G. Malm et al.
Neonatal herpes simplex virus infections: HSV DNA in cerebrospinal fluid and serum
Arch Dis Child Fetal Neonatal Ed
(1999)
H. Kimura et al.
Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid
J Infect Dis
(1991)
H. Kimura et al.
Quantitation of viral load in neonatal herpes simplex virus infection and comparison between type 1 and type 2
J Med Virol
(2002)
C. Diamond et al.
Viremia in neonatal herpes simplex virus infections
Pediatr Infect Dis J
(1999)

R. Whitley et al.

A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group

N Engl J Med

(1991)

R.L. Ashley et al.

Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera

J Clin Microbiol

(1988)

R. Ashley-Morrow et al.

Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2

Sex Transm Dis

(2003)

A. Langenberg et al.

Comparison of diploid fibroblast and rabbit kidney tissue cultures and a diploid fibroblast microtiter plate system for the isolation of herpes simplex virus

J Clin Microbiol

(1988)

W.E. Lafferty et al.

Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population

J Clin Microbiol

(1987)

K.R. Jerome et al.

Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR

J Clin Microbiol

(2002)

A.S. Magaret et al.

Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa

J Clin Microbiol

(2007)

L. Corey et al.

Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay

J Med Virol

(2005)

D.W. Kimberlin et al.

Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections

Pediatrics

(2001)

Cited by (49)

A broad-based probe-free qPCR assay for detection and discrimination of three human herpes viruses
2023, Journal of Virological Methods
Primary infection or reactivation of latent human cytomegalovirus (HCMV) or herpes simplex viruses (HSV) 1 or 2 during pregnancy can transmit the virus in utero or during natural childbirth to the fetus. The majority of these infections are asymptomatic at birth but may present later with potentially lethal disseminated infection or meningitis (HSV), or long-term neurodevelopmental sequelae including sensorineural hearing loss or neurodevelopmental impairments (HCMV). Unfortunately, early signs and symptoms of disseminated viral infections may be misdiagnosed as bacterial sepsis. Therefore, immediate testing for viral etiologies may not be ordered or even considered by skilled clinicians. In asymptomatic HCMV infections, early detection is necessary to monitor for and treat future neurologic sequelae. In acutely ill-appearing infants, specific detection of viruses against other disease-causing agents is vital to inform correct patient management, including early administration of the correct antimicrobial(s). An ideal test should be rapid, inexpensive, require low sample volumes, and demonstrate efficacy in multiple tissue matrices to aid in timely clinical decision-making for neonatal infections. This work discusses the development of a rapid probe-free qPCR assay for HSV and HCMV that enables early and specific detection of these viruses in neonates. The assay’s probe free chemistry would allow easier extension to a broad-based multiplexed pathogenic panel as compared to assays utilizing sequence-specific probes or nested PCR.
Neonatal Herpes Simplex Virus Infections
2023, Principles of Neonatology
The incidence of neonatal herpes simplex virus (HSV) infection is about 1 in 3200 to 10,000 live births. Neonatal herpes disease may be acquired prenatally (congenital herpes) or around birth (perinatally) in approximately 85% of infections, which may lead to hydrops fetalis and fetal death, or acquired after birth in about 10% of infections. Survivors of congenital herpes may exhibit a triad of skin eruptions or scarring, eye involvement with microcephaly, or hydranencephaly. Neonatal herpes has been classified into three main therapeutic and prognostic types: skin, eye, and mouth (SEM); central nervous system with or without SEM; and disseminated disease. The diagnosis is through isolation of HSV in culture media, detection of herpes DNA by polymerase chain reaction, or direct fluorescent antibody herpes antigen detection. Interpretation of these tests depends on the clinical situations. A full evaluation is needed for all neonates with suspected or proven herpes infection. The differential diagnosis of neonatal HSV is broad and includes infectious and noninfectious conditions. Empiric therapy for neonatal HSV may be warranted after appropriate microbiologic specimens are obtained. Acyclovir is the treatment of choice for all types of neonatal herpes disease. The duration of intravenous treatment is based on clinical situations, and response to therapy ranges from 14 to 21 days. Ocular involvement needs eye drops and an ophthalmology consult. Six months to one year of oral acyclovir suppressive treatment should be started immediately following parenteral acyclovir for all types of neonatal herpes disease.
Viral Infections of the Fetus and Newborn
2023, Avery's Diseases of the Newborn
Viral infections of the fetus and newborn are common and frequently under recognized. Viral infections can be acquired in utero, intrapartum, or postpartum. The outcome of infection frequently depends on the timing of acquisition. The consequences of some infections can be evident at birth when infants present with symptoms such as intrauterine growth restriction, hepatitis, thrombocytopenia, and neurologic abnormalities. In other infections, the infant may be asymptomatic at birth but develop severe disease in the neonatal period. Timely and specific identification of viral infections is important as there are an increasing number of antiviral therapeutic agents available and appropriate treatment can be lifesaving. Identification of viral disease in the neonate may also provide important prognostic information, particularly for viruses associated with a high risk of neurodevelopmental issues. Accordingly, making a diagnosis of a viral infection can help to direct and focus long-term management. Fortunately, with the availability of molecular tools for specific viral detection using polymerase chain reaction (PCR) amplification of viral nucleic acid, virtually all pathogenic viruses can be rapidly identified. This chapter reviews the epidemiology, pathogenesis, diagnosis, clinical management, outcomes, and prevention of many common congenital and perinatal viral infections encountered in neonates.
Maternal-fetal infections: Herpes simplex virus infection and pregnancy
2021, Option/Bio
Pregnancy and viral infections: Mechanisms of fetal damage, diagnosis and prevention of neonatal adverse outcomes from cytomegalovirus to SARS-CoV-2 and Zika virus
2021, Biochimica et Biophysica Acta - Molecular Basis of Disease
Some maternal infections, contracted before or during pregnancy, can be transmitted to the fetus, during gestation (congenital infection), during labor and childbirth (perinatal infection) and through breastfeeding (postnatal infection). The agents responsible for these infections can be viruses, bacteria, protozoa, fungi. Among the viruses most frequently responsible for congenital infections are Cytomegalovirus (CMV), Herpes simplex 1–2, Herpes virus 6, Varicella zoster. Moreover Hepatitis B and C virus, HIV, Parvovirus B19 and non-polio Enteroviruses when contracted during pregnancy may involve the fetus or newborn at birth. Recently, new viruses have emerged, SARS-Cov-2 and Zika virus, of which we do not yet fully know the characteristics and pathogenic power when contracted during pregnancy.
Viral infections in pregnancy can damage the fetus (spontaneous abortion, fetal death, intrauterine growth retardation) or the newborn (congenital anomalies, organ diseases with sequelae of different severity). Some risk factors specifically influence the incidence of transmission to the fetus: the timing of the infection in pregnancy, the order of the infection, primary or reinfection or chronic, the duration of membrane rupture, type of delivery, socio-economic conditions and breastfeeding. Frequently infected neonates, symptomatic at birth, have worse outcomes than asymptomatic. Many asymptomatic babies develop long term neurosensory outcomes.
The way in which the virus interacts with the maternal immune system, the maternal-fetal interface and the placenta explain these results and also the differences that are observed from time to time in the fetal‑neonatal outcomes of maternal infections. The maternal immune system undergoes functional adaptation during pregnancy, once thought as physiological immunosuppression. This adaptation, crucial for generating a balance between maternal immunity and fetus, is necessary to promote and support the pregnancy itself and the growth of the fetus. When this adaptation is upset by the viral infection, the balance is broken, and the infection can spread and lead to the adverse outcomes previously described. In this review we will describe the main viral harmful infections in pregnancy and the potential mechanisms of the damages on the fetus and newborn.
Pediatric Fever
2021, Emergency Medicine Clinics of North America

View all citing articles on Scopus

: Supported by the National Institutes of Health (P01 AI030731 [to A.W., K.M., A.M., L.D., L.C., J.S.] and K23AI087206 [to J.S.]). A.W. receives grants from the National Institutes of Health, Gilead, Vical, Agenus, and Genocea, and personal fees from Aicuris. L.C. is on the scientific advisory board for and holds stock (<1% of company) in Immune Design Corp, and is a coinventor listed on several patents involving potential HSV vaccine development. The other authors declare no conflicts of interest.

View full text

Original ArticlePlasma and Cerebrospinal Fluid Herpes Simplex Virus Levels at Diagnosis and Outcome of Neonatal Infection

Objective

Study design

Results

Conclusions

Section snippets

Methods

Results

Discussion

J Pediatr

Lancet

Cost-effectiveness analysis of herpes simplex virus testing and treatment strategies in febrile neonates

Arch Pediatr Adolesc Med

Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention

Virol J

Diagnosis of herpes simplex virus in the era of polymerase chain reaction

Pediatr Infect Dis J

Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

J Infect Dis

Neonatal herpes simplex virus infections: HSV DNA in cerebrospinal fluid and serum

Arch Dis Child Fetal Neonatal Ed

Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid

J Infect Dis

Quantitation of viral load in neonatal herpes simplex virus infection and comparison between type 1 and type 2

J Med Virol

Viremia in neonatal herpes simplex virus infections

Pediatr Infect Dis J

A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group

N Engl J Med

Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera

J Clin Microbiol

Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2

Sex Transm Dis

Comparison of diploid fibroblast and rabbit kidney tissue cultures and a diploid fibroblast microtiter plate system for the isolation of herpes simplex virus

J Clin Microbiol

Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population

J Clin Microbiol

Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR

J Clin Microbiol

Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa

J Clin Microbiol

Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay

J Med Virol

Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections

Pediatrics

Original Article
Plasma and Cerebrospinal Fluid Herpes Simplex Virus Levels at Diagnosis and Outcome of Neonatal Infection